KR23343 Phase 1 Study in Healthy Adults

Phase 1, randomised, double-blind trial of KR23343 (12 arms), sponsored by Jiangxi Kvvit Pharmaceutical. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events, Serious Adverse Event(s) (SAEs), And Adverse Events Leading To Study Discontinuation at 16 days and Number of participants with abnormal laboratory test results, abnormal vital signs, abnormal physical examination findings, and abnormal ECG parameters at 16 days. Started Feb 2026; status: recruiting.